3.755USD-3.72%Mkt Cap: 288.27M USDP/E: —Last update: 2026-05-26
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap288.27M USD
Enterprise Value190.11M USD
Revenue (TTM)—
Gross Profit-33.35M USD
Net Income (TTM)13.27M USD
Revenue/Share—
Last Price3.755 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.26
PEG—
EV/EBITDA-3.45
EV/Revenue—
P/S—
P/B1.27
EPS (TTM)-0.58
EPS (Forward)-0.89
52W Range
1.60043% of range6.600
52W High6.600 USD
52W Low1.600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE8.76%
ROA7.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-44.78M USD
CapEx (TTM)933.16K USD
FCF Margin—
FCF Yield-10.92%
Net Debt-101.22M USD
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity0.04
Current Ratio11.45
Quick Ratio11.06
Book Value/Sh3.000 USD
Cash/Share1.404 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 5, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)10.00 USD
Target Range6.000 USD – 15.00 USD
# Analysts9
Ownership
Shares Out.76.46M
Float52.34M
Insiders0.84%
Institutions91.88%
Short Interest
Short Ratio5.7d
Short % Float3.59%
Short % Out.3.44%
Shares Short2.42M
Short (prev mo.)2.50M
Technical
SMA 503.813 (-1.5%)
SMA 2003.373 (+11.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)876.50K
Avg Vol (10d)1.41M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—